Information for you
On this page, you will find information on the Agency’s activities that are most relevant to healthcare professionals, including news, and events.
You can contribute to the Agency’s work by responding to public consultations.
Learn more about how patients and consumers are actively involved in the work of the Agency.
Newsletter - Human medicines highlights
This newsletter is addressed primarily to organisations representing healthcare professionals, patients and consumers. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency (EMA).
Patients and consumers meetings and training sessions
Training day for patients and consumers involved in European Medicines Agency activities (November 2014) - See the agenda and all related documents of the latest training day for patients and consumers.
Meeting with PCWP and all eligible patient and consumer organisations (November 26) - See the agenda and all related documents of the latest European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting.
Record number of medicines for Rare Diseases recommended for approval in 2014
In 2014, the EMA recommended the highest number of orphan designated medicines for marketing authorisation in a year. 17 medicines for human use out of the 82 recommended in 2014, are intended for the treatment of a rare disease, providing therapies for patients who often have only few or no treatment options.
Reporting side effects
As a patient, you can report side effects of medicines directly to the authorities. The EMA has published a leaflet in all EU languages on how to report side effects for yourself or on behalf of someone in your care. You usually do this by filling in a form available online or from your doctor or pharmacist.
You can also use the European database of suspected adverse drug reaction reports to see information on suspected side effects reported with thousands of different medicines.
News for patients and carers
Five new medicines, including one orphan, recommended for approval ... Read more
Vaccine covers five more types of HPV than previously approved Gardasil vaccine ... Read more
Lenvima offers treatment option for patients who no longer respond to standard therapy ... Read more
Measures for other intravenous bisphosphonates and denosumab to be considered in upcoming reviews ... Read more
New restrictions to minimise the risks of effects on heart rhythm with hydroxyzine-containing medicines
Use to be avoided in patients at greatest risk and doses to be kept low ... Read more
- See all News for patients and carers
Events of interest
The invitation-only conference is organised to celebrate the 20th anniversary of the European Medicines Agency. Looking back at the past two decades, the Agency is proud of its successes, impressive growth and achievements. Yet, in addition to celebrating past successes, the Agency has its eyes firmly set in the challenges of the future. Cognisant of its pivotal role at the crossroads of life science research and development, patient care, public health policy and law, the Agency will use this event to explore with a range of stakeholders how best to deliver its role in the future. ... Read more
The aim of the meeting is to develop ways to work together that optimise the design and conduct of neonatal medicines research in Europe. During this meeting we will share perspectives about the current state of neonatal medicines research in Europe, review “hot topics” and prioritise them, and develop an action plan for 2015. Registration by invitation only. ... Read more
19/02/2015 - 20/02/2015
The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) is a five-year public-private partnership of 34 partners, which was initiated in 2009 to enhance the monitoring of the safety of medicinal products and contribute to better evaluate and communicate their benefit-risk profile throughout their lifecycle. To this end, PROTECT planned to develop and test methodological standards and innovative tools. The objective of this final PROTECT symposium is to present the main results and recommendations of PROTECT and discuss their implications from a methodological perspective and for the evaluation of the benefits and risks of medicines. Four parallel pre-symposium training courses provide in-depth training on specific aspects of the research work performed in PROTECT. Registration closed. ... Read more
04/12/2014 - 05/12/2014
European Medicines Agency/European Federation of Pharmaceutical Industries and Associations workshop on the importance of dose finding and dose selection for the successful development, licensing and lifecycle management of medicinal products
EMA/EFPIA workshop is planned for 4-5 December 2014 to discuss the importance of dose finding and dose selection for the successful development, licensing and lifecycle management of medicinal products. Registration: please register by 19 September 2014 using the registration form provided. ... Read more
European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - Workshop on benefit-risk communication
This is a joint Workshop with representatives from patients', consumers' and healthcare professionals' organisations. The workshop will provide an overview of how EMA communicates on the benefits and risks of medicines within the EU regulatory network. It will also discuss the role of communication in achieving effectiveness of risk minimisation measures and explore how such communication can support healthcare professionals and patients on their treatment decisions. Registration by invitation only. ... Read more
- See all Events of interest